Stella Pharma Corporation
【Stellapharma】Share Issue and Fundraising Plan｜June 2026
Stellapharma plans to issue 1,000,000 new shares and 10,500 stock acquisition rights to the allottee through a second third-party allotment in June 2026, raising approximately ¥779 million. The funds will be allocated to clinical trials for rare and deep-seated cancers and research and development efforts.
Key Figures
- Funds raised: approximately ¥779 million
- Number of new shares issued: 1,000,000 shares
- Number of stock acquisition rights: 10,500 units
AI要約
Overview of Capital Policy
Stellapharma plans to issue new shares and stock acquisition rights to the allottee through a second third-party allotment in June 2026, raising approximately ¥779 million. The funds will be used for clinical trials and research on rare and deep-seated cancers, R&D, and overseas expansion. This aims to support future business expansion and establish a stable financial foundation. The issuance terms are set at 92% of the stock price, ensuring fair pricing. The post-issuance share dilution rate is judged to be within a reasonable range at 6.02%.
Future Outlook and Impact on Shareholders
The fundraising, with a relatively low dilution rate of 6.02%, aims to secure necessary funds for business expansion. The proceeds will be allocated to clinical trials and research on rare and deep-seated cancers, contributing to long-term corporate value enhancement. While shareholder ownership may be diluted, it is based on rationality of the fundraising and growth strategy, aiming to increase investment value.
Stella Pharma Corporation
Company overview · Stock price · Financial data · All IR
